keyword
https://read.qxmd.com/read/37142291/talimogene-laherparepvec-in-combination-with-ipilimumab-versus-ipilimumab-alone-for-advanced-melanoma-5-year-final-analysis-of-a-multicenter-randomized-open-label-phase-ii-trial
#21
JOURNAL ARTICLE
Jason A Chesney, Igor Puzanov, Frances A Collichio, Parminder Singh, Mohammed M Milhem, John Glaspy, Omid Hamid, Merrick Ross, Philip Friedlander, Claus Garbe, Theodore Logan, Axel Hauschild, Celeste Lebbé, Harshada Joshi, Wendy Snyder, Janice M Mehnert
Talimogene laherparepvec (T-VEC) plus ipilimumab has demonstrated greater antitumor activity versus ipilimumab alone, without additional toxicity, in patients with advanced melanoma. Here, we report the 5-year outcomes from a randomized phase II study. These data provide the longest efficacy and safety follow-up for patients with melanoma treated with a combination of an oncolytic virus and a checkpoint inhibitor.Eligible patients with unresectable stage IIIB‒IV melanoma were randomized 1:1 to receive T-VEC plus ipilimumab or ipilimumab alone...
May 2023: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/37114291/efficacy-of-imiquimod-in-the-management-of-lentigo-maligna
#22
JOURNAL ARTICLE
Marie Daude, Monica Dinulescu, Jean-Michel Nguyen, Hervé Maillard, Florence Le Duff, Laurent Machet, Marie Beylot-Barry, Delphine Legoupil, Ewa Wierzbicka-Hainaut, Christophe Bedane, Marie Thérèse Leccia, Sébastien Debarbieux, Nicolas Meyer, Sandrine Monestier, Guido Bens, Marc G Denis, Celine Bossard, Beatrice Vergier, Amir Khammari, Brigitte Dréno
BACKGROUND: Lentigo maligna (LM) is a melanocytic proliferation occurring on photo-exposed skin that may progress to LM melanoma. Surgery is recommended as first-line treatment. Excision margins of 5-10 mm remain, without international consensus. Several studies have shown that imiquimod, an immunomodulator, induces LM regression. This study investigated the effect of imiquimod versus placebo in neoadjuvant settings. PATIENTS AND METHODS: We performed a prospective, randomized, multicentre, phase III clinical study...
April 27, 2023: Journal of the European Academy of Dermatology and Venereology: JEADV
https://read.qxmd.com/read/36900196/advances-in-intralesional-therapy-for-locoregionally-advanced-and-metastatic-melanoma-five-years-of-progress
#23
REVIEW
Danielle K DePalo, Jonathan S Zager
Locoregionally advanced and metastatic melanoma are complex diagnoses with a variety of available treatment options. Intralesional therapy for melanoma has been under investigation for decades; however, it has advanced precipitously in recent years. In 2015, the Food and Drug Administration (FDA) approved talimogene laherparepvec (T-VEC), the only FDA-approved intralesional therapy for advanced melanoma. There has been significant progress since that time with other oncolytic viruses, toll-like receptor agonists, cytokines, xanthene dyes, and immune checkpoint inhibitors all under investigation as intralesional agents...
February 23, 2023: Cancers
https://read.qxmd.com/read/36900146/high-frequency-ultrasound-in-diagnosis-and-treatment-of-non-melanoma-skin-cancer-in-the-head-and-neck-region
#24
JOURNAL ARTICLE
Tiberiu Tamas, Cristian Dinu, Lavinia Manuela Lenghel, Emil Boțan, Adela Tamas, Sebastian Stoia, Daniel Corneliu Leucuta, Simion Bran, Florin Onisor, Grigore Băciuț, Gabriel Armencea, Mihaela Băciuț
Non-melanoma skin cancer is one of the most frequently diagnosed cancers in the human body and unfortunately the incidence continues to increase. NMSC is represented by the basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs), which are the most prevalent forms, and basosquamous cell carcinomas (BSC) together with Merkel cell carcinoma (MCC), which are rare types but with a very aggressive pattern and poor prognosis. The pathological diagnosis is hard to assess without a biopsy, even by the dermoscopy...
March 6, 2023: Diagnostics
https://read.qxmd.com/read/36884194/efficacy-and-safety-of-needle-free-jet-injector-assisted-intralesional-treatments-in-dermatology-a-systematic-review
#25
REVIEW
Vazula Zulfra Bekkers, Liora Bik, Johanna Catharina van Huijstee, Albert Wolkerstorfer, Errol Prospero Prens, Martijn Bastiaan Adriaan van Doorn
Needle-free jet injectors are used for the intralesional treatment of various dermatological indications. However, a systematic review that evaluates the efficacy and safety of these treatments has not been published. The objectives of this study are to evaluate the efficacy and safety of needle-free jet injections for dermatological indications and to provide evidence-based treatment recommendations. An electronic literature search was conducted in April 2022. Two reviewers independently selected studies based on predefined criteria and performed a methodological quality assessment using the Cochrane Collaborations risk-of-bias 2...
June 2023: Drug Delivery and Translational Research
https://read.qxmd.com/read/36860805/four-cases-of-disseminated-herpes-simplex-virus-following-talimogene-laherparepvec-injections-for-unresectable-metastatic-melanoma
#26
JOURNAL ARTICLE
Kate E Beekman, Lily M Parker, Danielle K DePalo, Kelly M Elleson, Amod A Sarnaik, Kenneth Y Tsai, Bethany M Withycombe, Jonathan S Zager
No abstract text is available yet for this article.
March 2023: JAAD Case Reports
https://read.qxmd.com/read/36720361/-translated-article-rf-intralesional-5-fluorouracil-in-the-treatment-of-nonmelanoma-skin-cancer
#27
JOURNAL ARTICLE
J Gil-Lianes, D Morgado-Carrasco
No abstract text is available yet for this article.
March 2023: Actas Dermo-sifiliográficas
https://read.qxmd.com/read/36624340/multimodal-single-cell-and-whole-genome-sequencing-of-small-frozen-clinical-specimens
#28
JOURNAL ARTICLE
Yiping Wang, Joy Linyue Fan, Johannes C Melms, Amit Dipak Amin, Yohanna Georgis, Irving Barrera, Patricia Ho, Somnath Tagore, Gabriel Abril-Rodríguez, Siyu He, Yinuo Jin, Jana Biermann, Matan Hofree, Lindsay Caprio, Simon Berhe, Shaheer A Khan, Brian S Henick, Antoni Ribas, Evan Z Macosko, Fei Chen, Alison M Taylor, Gary K Schwartz, Richard D Carvajal, Elham Azizi, Benjamin Izar
Single-cell genomics enables dissection of tumor heterogeneity and molecular underpinnings of drug response at an unprecedented resolution1-11 . However, broad clinical application of these methods remains challenging, due to several practical and preanalytical challenges that are incompatible with typical clinical care workflows, namely the need for relatively large, fresh tissue inputs. In the present study, we show that multimodal, single-nucleus (sn)RNA/T cell receptor (TCR) sequencing, spatial transcriptomics and whole-genome sequencing (WGS) are feasible from small, frozen tissues that approximate routinely collected clinical specimens (for example, core needle biopsies)...
January 9, 2023: Nature Genetics
https://read.qxmd.com/read/36513855/anterior-segment-optical-coherence-tomography-in-ocular-surface-tumours-and-simulating-lesions
#29
REVIEW
Ahmet Kaan Gündüz, Ibadulla Mirzayev, Aylin Okcu Heper, Işınsu Kuzu, Zarifakhanim Gahramanli, Cevriye Cansiz Ersöz, Ömür Özlenen Gündüz, Ömür Ataoğlu
This study aims to systematically review the reported literature on the use of anterior segment optical coherence tomography (AS-OCT) in ocular surface tumours and simulating lesions. A systematic literature search was done using PubMed, Scopus, and Web of Science databases between January 2002 and December 2021. On AS-OCT, ocular surface squamous neoplasia typically demonstrate epithelial thickening, epithelial hyperreflectivity, and an abrupt transition between normal and abnormal epithelium. Conjunctival nevi usually show mildly hyperreflective epithelium of normal thickness, internal hyperreflectivity, and intralesional cysts which is the hallmark of this tumour...
April 2023: Eye
https://read.qxmd.com/read/36454284/talimogene-laherparepvec-monotherapy-for-head-and-neck-melanoma-patients
#30
JOURNAL ARTICLE
Viola Franke, Emma H A Stahlie, Willem M C Klop, Charlotte L Zuur, Danique M S Berger, Bernies van der Hiel, Bart A van de Wiel, Michel W J M Wouters, Winan J van Houdt, Alexander C J van Akkooi
Talimogene laherparepvec (T-VEC) is a modified herpes simplex virus, type 1, intralesionally administered in patients with stage IIIB/C-IVM1a unresectable melanoma. When surgery is not a treatment option in the head and neck region, T-VEC can be an elegant alternative to systemic immunotherapy. Ten patients with metastatic melanoma in the head and neck region started treatment with T-VEC monotherapy at the Netherlands Cancer Institute. We collected data on response, adverse events (AEs), and baseline characteristics...
November 29, 2022: Melanoma Research
https://read.qxmd.com/read/36442254/burden-of-care-for-patients-with-in-transit-melanoma
#31
JOURNAL ARTICLE
Zoey Duncan, Natalie Garcia, Tanya Correya, Chimaraije Amu-Nnadi, Kristy Broman
INTRODUCTION: Patient burden of cancer care can be significant, especially for cancers like melanoma where patients are living longer, even with advanced disease. The purpose of this study is to compare the burden of treatment of melanoma patients with in-transit metastases (ITM). There are multiple treatment options for ITM, but no standard due to lack of large cohort comparative studies; thus, the anticipated burden of care may influence therapy choice. METHODS: Included patients had in-transit melanoma without distant metastasis and were managed at our institution from July 1, 2015 through December 31, 2020 using a combination of surgery, systemic, intralesional, and radiation therapy...
November 25, 2022: Journal of Surgical Research
https://read.qxmd.com/read/36113608/rf-intralesional-5-fluorouracil-in-the-treatment-of-nonmelanoma-skin-cancer
#32
JOURNAL ARTICLE
J Gil-Lianes, D Morgado-Carrasco
No abstract text is available yet for this article.
March 2023: Actas Dermo-sifiliográficas
https://read.qxmd.com/read/35927710/neoadjuvant-nivolumab-t-vec-combination-therapy-for-resectable-early-stage-or-metastatic-iiib-ivm1a-melanoma-with-injectable-disease-study-protocol-of-the-nivec-trial
#33
JOURNAL ARTICLE
Maartje W Rohaan, Emma H A Stahlie, Viola Franke, Lisanne P Zijlker, Sofie Wilgenhof, Vincent van der Noort, Alexander C J van Akkooi, John B A G Haanen
BACKGROUND: Trials investigating neoadjuvant treatment with immune checkpoint inhibitors (ICI) in patients with melanoma have shown high clinical and pathologic response rates. Treatment with talimogene laherparepvec (T-VEC), a modified herpes simplex virus type-1 (HSV-1), is approved for patients with unresectable stage IIIB-IVM1a melanoma and has the potential to make tumors more susceptible for ICI. Combination ICI and intralesional T-VEC has already been investigated in patients with unresectable stage IIIB-IV disease, however, no data is available yet on the potential benefit of this combination therapy in neoadjuvant setting...
August 4, 2022: BMC Cancer
https://read.qxmd.com/read/35869314/electrochemotherapy-of-skin-metastases-from-malignant-melanoma-a-prisma-compliant-systematic-review
#34
REVIEW
Martina Ferioli, Valentina Lancellotta, Anna Myriam Perrone, Alessandra Arcelli, Andrea Galuppi, Lidia Strigari, Milly Buwenge, Francesca De Terlizzi, Silvia Cammelli, Roberto Iezzi, Pierandrea De Iaco, Luca Tagliaferri, Alessio G Morganti
The main treatment of MM metastases are systemic therapies, surgery, limb perfusion, and intralesional talimogene laherparepvec. Electrochemotherapy (ECT) is potentially useful also due to the high response rates recorded in cancers of any histology. No randomized studies comparing ECT with other local therapies have been published on this topic. We analyzed the available evidence on efficacy and toxicity of ECT in this setting. PubMed, Scopus, and Cochrane databases were screened for paper about ECT on MM skin metastases...
October 2022: Clinical & Experimental Metastasis
https://read.qxmd.com/read/35847508/-pincer-movement-reversing-cisplatin-resistance-based-on-simultaneous-glutathione-depletion-and-glutathione-s-transferases-inhibition-by-redox-responsive-degradable-organosilica-hybrid-nanoparticles
#35
JOURNAL ARTICLE
Boyi Niu, Yixian Zhou, Kaixin Liao, Ting Wen, Sixian Lao, Guilan Quan, Xin Pan, Chuanbin Wu
The therapeutic efficacy of cisplatin has been restricted by drug resistance of cancers. Intracellular glutathione (GSH) detoxification of cisplatin under the catalysis of glutathione S -transferases (GST) plays important roles in the development of cisplatin resistance. Herein, a strategy of "pincer movement" based on simultaneous GSH depletion and GST inhibition is proposed to enhance cisplatin-based chemotherapy. Specifically, a redox-responsive nanomedicine based on disulfide-bridged degradable organosilica hybrid nanoparticles is developed and loaded with cisplatin and ethacrynic acid (EA), a GST inhibitor...
April 2022: Acta Pharmaceutica Sinica. B
https://read.qxmd.com/read/35782876/inconsistencies-in-modeling-the-efficacy-of-the-oncolytic-virus-hsv1716-reveal-potential-predictive-biomarkers-for-tolerability
#36
JOURNAL ARTICLE
Faith Howard, Joe Conner, Sarah Danson, Munitta Muthana
Treatment with HSV1716 via intralesional administration has proven successful for melanoma patients with the hope that oncolytic virotherapy would become another weapon in the systemic anticancer therapy (SACT) arsenal. In addition to challenges surrounding the systemic delivery of oncolytic viruses (OVs), problems associated with its in vivo modeling have resulted in low predictive power, contributing to the observed disappointing clinical efficacy. As OV's efficacy is elicited through interaction with the immune system, syngeneic orthotopic mouse models offer the opportunity to study these with high reproducibility and at a lower cost; however, inbred animals display specific immune characteristics which may confound results...
2022: Frontiers in Molecular Biosciences
https://read.qxmd.com/read/35740539/beyond-immunotherapy-seizing-the-momentum-of-oncolytic-viruses-in-the-ideal-platform-of-skin-cancers
#37
REVIEW
Dimitrios C Ziogas, Anastasios Martinos, Dioni-Pinelopi Petsiou, Amalia Anastasopoulou, Helen Gogas
Despite the durable remissions induced by ICIs and targeted therapies in advanced melanoma and non-melanoma skin cancers, both subtypes usually relapse. Many systematic therapies have been tested to increase efficacy and delay relapse in ICIs, but their success has been limited. Due the feasibility of this approach, skin cancers have become the ideal platform for intralesional infusions of many novel agents, including oncolytic viruses (OVs). Talimogene laherparepvec (T-VEC) was the first FDA-approved OV for the treatment of unresectable melanoma and this virus opened up further potential for the use of this class of agents, especially in combination with ICIs, in order to achieve deeper and longer immune-mediated responses...
June 10, 2022: Cancers
https://read.qxmd.com/read/35732347/bcg-hydrogel-promotes-ctss-mediated-antigen-processing-and-presentation-thereby-suppressing-metastasis-and-prolonging-survival-in-melanoma
#38
JOURNAL ARTICLE
Mirela Kremenovic, Alfred A Chan, Bing Feng, Lukas Bäriswyl, Steve Robatel, Thomas Gruber, Li Tang, Delphine J Lee, Mirjam Schenk
BACKGROUND: The use of intralesional Mycobacterium bovis BCG (intralesional live BCG) for the treatment of metastatic melanoma resulted in regression of directly injected, and occasionally of distal lesions. However, intralesional-BCG is less effective in patients with visceral metastases and did not significantly improve overall survival. METHODS: We generated a novel BCG lysate and developed it into a thermosensitive PLGA-PEG-PLGA hydrogel (BCG hydrogel), which was injected adjacent to the tumor to assess its antitumor effect in syngeneic tumor models (B16F10, MC38)...
June 2022: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/35658500/double-trouble-immunotherapy-doublets-in-melanoma-approved-and-novel-combinations-to-optimize-treatment-in-advanced-melanoma
#39
JOURNAL ARTICLE
Florentia Dimitriou, Axel Hauschild, Janice M Mehnert, Georgina V Long
Immune checkpoint inhibitors, particularly anti-PD-1-based immune checkpoint inhibitors, have dramatically improved outcomes for patients with advanced melanoma and are currently deemed a standard of care. Ipilimumab/nivolumab is the first combination of immune checkpoint inhibitors to improve progression-free survival and overall survival in the first-line setting, with durable responses and the longest median overall survival, 72.1 months, of any drug therapy approved for advanced melanoma. However, its use is limited by the high rate of severe (grade 3-4) treatment-related adverse events...
April 2022: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/35656636/a-phase-i-study-of-the-safety-and-efficacy-of-talimogene-laherparepvec-in-japanese-patients-with-advanced-melanoma
#40
JOURNAL ARTICLE
Naoya Yamazaki, Taiki Isei, Yoshio Kiyohara, Hiroshi Koga, Takashi Kojima, Tatsuya Takenouchi, Kenji Yokota, Kenjiro Namikawa, Min Yi, Alissa Keegan, Satoshi Fukushima
Talimogene laherparepvec (T-VEC) is approved for the treatment of unresectable melanoma in the US, Europe, and Australia. This phase I, multicenter, open-label, dose de-escalation study evaluated the safety and efficacy of T-VEC in Japanese patients with unresectable stage IIIB-IV melanoma. Eligible adult patients had histologically confirmed stage IIIB-IVM1c cutaneous melanoma, may have received prior systemic anticancer therapy, must have had ≥ 1 injectable lesion, serum lactate dehydrogenase ≤ 1...
June 2, 2022: Cancer Science
keyword
keyword
106246
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.